Journal article icon

Journal article

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC

Abstract:

Homoharringtonine, a plant alkaloid, has been reported to suppress protein synthesis and has been approved by the US Food and Drug Administration for the treatment of chronic myeloid leukemia. Here we show that in acute myeloid leukemia (AML), homoharringtonine potently inhibits cell growth/viability and induces cell cycle arrest and apoptosis, significantly inhibits disease progression in vivo, and substantially prolongs survival of mice bearing murine or human AML. Strikingly, homoharringto...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.3324/haematol.2018.208835

Authors


More by this author
Institution:
University of Oxford
Department:
NDM
Sub department:
Target Discovery Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Oxford Ludwig Institute
Role:
Author
ORCID:
0000-0003-0096-4187
Publisher:
Ferrata Storti Foundation
Journal:
Haematologica More from this journal
Volume:
105
Issue:
1
Pages:
148-160
Publication date:
2019-04-11
Acceptance date:
2019-04-09
DOI:
EISSN:
1592-8721
ISSN:
0390-6078
Language:
English
Keywords:
Pubs id:
pubs:1010400
UUID:
uuid:fce20f72-9a41-43b4-ba9f-7ed6b653fe93
Local pid:
pubs:1010400
Source identifiers:
1010400
Deposit date:
2019-06-10

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP